PMV Pharmaceuticals (NASDAQ:PMVP) versus Evotec (NASDAQ:EVO) Head-To-Head Comparison

PMV Pharmaceuticals (NASDAQ:PMVP) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Insider and Institutional Ownership

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

PMV Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for PMV Pharmaceuticals and Evotec, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	0	1	2.50
Evotec	1	1	3	0	2.40

Evotec has a consensus target price of $7.00, suggesting a potential upside of 116.72%. Given Evotec’s higher probable upside, analysts plainly believe Evotec is more favorable than PMV Pharmaceuticals.

Earnings & Valuation

This table compares PMV Pharmaceuticals and Evotec”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.96
Evotec	$891.97 million	1.29	-$117.12 million	N/A	N/A

PMV Pharmaceuticals has higher earnings, but lower revenue than Evotec.

Profitability

This table compares PMV Pharmaceuticals and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-59.07%	-54.19%
Evotec	-13.13%	-12.40%	-5.77%

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.